SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
VRCA reported Q3 2026 results. The price and volatility reaction is pending.
VRCAearnings

Earnings reactions, page 3

Verrica Pharmaceuticals Inc. (VRCA) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue for the three months ended September 30, 2026, was $6.9 million compared to $14.3 million for the three months ended September 30, 2025.
  • U.S. YCANTH net product revenue was $5.7 million for the quarter ended September 30, 2026, up 11.9% over the previous quarter and 57.9% year-over-year.
  • GAAP net loss was $12.4 million, or $0.58 per share, for the quarter ended September 30, 2026, compared to GAAP net loss of $0.3 million, or $0.03 per share, for the same period in 2025.
  • Non-GAAP net loss was $10.5 million, or $0.49 per share, for the quarter ended September 30, 2026, compared to non-GAAP net income of $1.1 million, or $0.12 per share, for the same period in 2025.
  • Research and development expenses were $7.6 million for the quarter ended September 30, 2026, compared to $2.2 million for the same period in 2025.
  • Selling, general and administrative expenses were $10.4 million for the quarter ended September 30, 2026, compared to $9.4 million for the same period in 2025.

Guidance

  • Verrica believes that its cash runway will extend into the fourth quarter of 2027, without giving effect to any potential clinical trial costs related to the study of VP-315 for the treatment of Gorlin syndrome.
  • Topline data readouts for the COVE-2 and COVE-3 Phase 3 trials in common warts are expected in the first quarter of 2027 and mid-2027, respectively.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →